differenti
diagnosi
new
pulmonari
infiltr
solid
organ
transplant
sot
recipi
divers
rang
noninfect
immunosuppress
toxic
invas
opportunist
infect
oi
invas
fungal
diseas
ifd
approxim
twothird
pulmonari
infiltr
infect
origin
prospect
preval
studi
european
sot
recipi
estim
incid
pneumonia
episod
per
sot
patientsyear
known
identifi
caus
pathogen
bacteria
virus
fungi
like
caus
organ
depend
degre
immunosuppress
time
post
transplant
local
epidemiolog
host
risk
factor
irrespect
aetiolog
develop
pulmonari
infiltr
sot
patient
associ
increas
mortal
significantli
higher
nosocomi
acquisit
infect
due
ifd
target
manag
approach
pulmonari
infiltr
sot
recipi
henc
requir
reduc
patient
mortal
outlin
approach
assess
diagnosi
empir
therapi
focu
ifd
includ
pneumocysti
jirovecii
pneumonia
pcp
viral
pathogen
consid
primari
insult
mani
pneumon
process
sot
recipi
respiratori
syncyti
viru
rsv
common
caus
communityacquir
pneumonia
cap
especi
intermedi
late
transplant
period
fig
cmv
commonli
encount
isol
viraemia
coliti
hepat
sot
recipi
pneumon
uncommon
outsid
lung
sot
cohort
pneumon
incid
reduc
patient
sirolimusbas
immunosuppress
influenza
associ
signific
morbid
mortal
especi
occur
earli
posttranspl
andor
lung
transplant
recipi
risk
influenza
infect
consist
across
post
transplant
period
addit
risk
puls
steroid
reject
lymphocyt
deplet
note
clinic
present
may
atyp
pandem
cough
myalgia
common
symptom
prospect
multicentr
point
preval
studi
europ
pneumonia
identifi
primarili
late
complic
commun
acquir
bacteri
origin
rate
bacteri
pneumonia
sot
upward
common
bacteria
isol
report
staphylococcu
aureu
pseudomona
aeruginosa
streptococcu
pneumonia
stenotrophomona
maltophilia
mortal
modern
cohort
empir
therapi
target
toward
local
epidemiolog
routin
microbiolog
less
frequent
nocardiosi
present
bronchopneumonia
howev
classic
descript
nodular
radiolog
appear
without
cavit
halo
sign
nocardia
affect
sot
recipi
tradit
sot
lung
grow
infect
rate
lung
sot
rate
heart
intestin
kidney
liver
recipi
respect
infect
typic
occur
within
first
second
year
post
transplant
median
time
infect
month
risk
factor
similar
oi
name
increas
immunosuppress
corticosteroid
high
plasma
calcineurin
level
preced
day
legionella
spp
anoth
bacteria
present
lobar
reticular
nodular
cavitari
pulmonari
diseas
sot
recipi
concurr
bacteraemia
rare
legionella
spp
suspect
specif
sputumb
cultur
pcr
request
mycobacteri
infect
occur
time
point
follow
sot
occur
frequent
lung
sot
frequenc
mycobacterium
tuberculosi
tb
caus
pulmonari
infiltr
depend
local
develop
countri
risk
nonetheless
still
higher
gener
popul
associ
mortal
lung
infiltr
primari
tb
manifest
sot
recipi
tb
infect
follow
pretranspl
treatment
latent
tb
rare
case
due
reactiv
rather
de
novo
acquisit
donorderiv
tb
tb
sot
modern
screen
practic
also
infrequ
pulmonari
tb
gener
present
protract
period
symptom
prior
diagnosi
median
day
although
tb
sot
occur
first
year
post
transplant
typic
late
manifest
median
month
spanish
sot
cohort
empir
therapi
tb
without
microbiolog
confirm
cultur
pcr
test
occur
without
high
probabl
diseas
consid
toxic
associ
therapi
liver
sot
heartlung
sot
renal
sot
potenti
rifampicininduc
disrupt
immunosuppress
regimen
although
caus
pathogen
fungu
diagnost
approach
pcp
discuss
separ
pcp
sot
earli
transplant
period
consid
rare
due
almost
univers
uptak
prophylaxi
predomin
trimethoprimsulfamethoxazol
reduc
risk
pcp
occur
frequent
heart
sot
recipi
per
patientyear
follow
kidney
per
patientyear
liver
transplant
recipi
per
patientyear
risk
factor
era
univers
prophylaxi
evalu
one
retrospect
case
control
studi
identifi
case
occur
second
year
post
transplant
age
total
lymphocyt
count
cmv
infect
establish
risk
factor
find
cmv
infect
lymphocyt
count
risk
factor
previous
demonstr
graft
reject
despit
second
year
post
sot
common
time
pcp
present
time
post
transplant
contrast
hiv
popul
diseas
sot
recipi
acut
sever
fulmin
respiratori
failur
common
fever
hypoxia
proport
physic
find
lymphadenopathi
uncommon
secondari
case
irrespect
secondari
prophylaxi
rel
uncommon
isol
case
outbreak
describ
sot
patient
without
obviou
risk
factor
pcp
pcp
remain
consid
differenti
patient
pneumonia
late
post
transplant
especi
known
risk
associ
present
concurr
outbreak
evid
estim
incid
ifd
sot
recipi
problemat
due
vari
definit
interpret
colonis
vs
invas
diseas
invas
aspergillosi
ia
remain
common
caus
pulmonari
ifd
incid
estim
broadli
common
infect
speci
aspergillu
fumigatu
infect
due
aspergillu
niger
aspergillu
terreu
aspergillu
flavu
also
encount
one
retrospect
studi
ia
account
ifd
overal
incid
ifd
among
lung
kidney
liver
heart
transplant
recipi
per
personyear
singl
transplant
centr
review
incid
pulmonari
ia
estim
renal
liver
heart
lung
sot
lung
sot
recipi
ia
estim
account
almost
ifd
recipientderiv
infect
may
relat
exposur
endem
fungi
eg
histoplasma
capsulatum
coccidioid
immiti
paracoccidioid
brasiliensi
activitiestravel
eg
rais
pigeon
cryptococcu
neoforman
marijuana
use
aspergillu
spp
transplantassoci
infect
surveil
network
trasnet
studi
histoplasmosi
commonli
report
endem
pathogen
incid
bimod
present
similar
seen
smaller
studi
first
month
year
post
sot
ifd
ia
less
frequent
report
invas
scedosporium
apiospermum
scedosporium
prolifican
donorderiv
infect
donor
neardrown
episod
prior
death
report
howev
scedosporium
spp
infect
commonli
diagnos
lung
transplant
recipi
evid
previou
colonis
scedosporium
spp
ifd
infrequ
liver
heart
transplant
recipi
scedosporium
spp
infect
associ
high
mortal
earli
post
sot
median
day
present
isol
pulmonari
dissemin
diseas
case
mucormycosi
report
affect
commonli
liver
lung
sot
patient
overal
contribut
approxim
ifd
associ
tcell
deplet
immunosuppress
regiment
common
pathogen
order
rhizopu
mucor
rhizomucor
cunninghamella
spp
cryptococcu
neoforman
incid
sot
recipi
caus
ifd
sot
recipi
frequent
occur
kidney
liver
sot
infect
typic
present
dissemin
diseas
occur
month
post
transplant
pulmonari
infiltr
occur
case
fusarium
spp
also
caus
ifd
transnet
studi
report
fusarium
ifd
pulmonari
present
dissemin
diseas
univers
risk
factor
ifd
amongst
sot
recipi
includ
environment
exposur
net
state
immunosuppress
overal
risk
factor
earli
month
post
sot
pulmonari
ia
includ
recurr
bacteri
infect
complic
postop
period
renal
failur
requir
dialysi
cmv
diseas
late
onset
ia
month
risk
factor
identifi
advanc
age
age
year
recurr
bacteri
infect
increas
immunosuppress
chronic
graft
reject
immunosuppressionrel
lymphoma
renal
failur
certain
sot
cohort
specif
addit
risk
factor
ia
exampl
aspergillu
spp
colonis
within
month
transplant
lung
sot
recipi
hepat
c
infect
pretranspl
fulmin
hepat
failur
liver
recipi
renal
transplant
patient
univers
risk
factor
includ
prolong
immunosuppress
ie
corticosteroid
graft
failur
requir
dialysi
heart
sot
addit
risk
factor
presenc
ia
episod
heart
transplant
program
month
addit
risk
studi
report
lung
sot
recipi
cystic
fibrosi
bronchiol
obliteran
airway
ischemia
hypogammaglobulinemia
bronchial
stent
singl
lung
transplant
ia
risk
factor
match
case
control
studi
zygomycosi
sot
associ
diabet
renal
failur
prior
voriconazol
caspofungin
use
clinic
present
ifd
vari
depend
type
sot
rang
asymptomat
colonis
tracheobronch
especi
lung
sot
local
invas
diseas
empyema
dissemin
fungal
tracheobronch
lead
local
ulcer
airway
obstruct
stent
occlus
dissemin
ifd
like
liver
lung
transplant
patient
onset
ifd
reportedli
occur
later
modern
cohort
commonli
greater
month
post
sot
gavalda
et
al
retrospect
case
control
studi
demonstr
ia
first
month
post
transplant
mean
time
day
rang
differ
mortal
ia
earli
month
late
month
post
sot
descript
earlier
onset
ia
compar
previou
report
may
relat
centrespecif
antifung
prophylaxi
recent
global
survey
lung
transplant
centr
indic
univers
prophylaxi
use
first
month
post
transplant
earli
preemptiveprophylaxi
therapi
colonis
patient
known
reduc
ifd
incid
ifdrel
mortal
cohort
renal
ia
report
later
sot
whilst
liver
lung
typic
earli
uniqu
lung
sot
ia
report
occur
site
anastomosi
mucormycosi
pulmonari
present
occur
case
risk
dissemin
higher
liver
sot
recipi
liver
transplant
patient
also
like
diseas
earlier
transplant
sot
recipi
median
time
transplant
mucormycosi
infect
sot
month
pulmonari
present
consolidationmass
nodular
cavit
cryptococcosi
although
pulmonari
present
occur
patient
fungaem
usual
concurr
dissemin
diseas
cn
involv
risk
dissemin
diseas
higher
liver
sot
recipi
sot
recipi
ia
hepat
insuffici
malnutrit
liver
lung
sot
prior
antibiot
therapi
mechan
ventil
transfus
therapi
cn
involv
associ
increas
risk
death
nonetheless
surviv
still
greater
sot
within
stem
cell
transplant
mortal
rate
mucormycosi
sot
demonstr
renal
failur
dissemin
diseas
associ
poorer
outcom
mortal
cryptococc
diseas
rang
respiratori
failur
present
prognosi
grave
use
tissu
biopsi
investig
pulmonari
infiltr
evalu
small
number
studi
primarili
pulmonari
nodul
mass
although
histopatholog
may
offer
method
diagnosi
differenti
within
fungu
genusclass
retrospect
singl
centr
review
lung
liver
renal
heart
sot
recipi
percutan
lung
biopsi
perform
procedur
yield
diagnosi
case
diagnost
yield
increas
core
biopsi
perform
addit
fine
needl
aspir
ia
combin
lung
biopsi
cultur
demonstr
diagnos
mucormycosi
sot
patient
ifd
predomin
thorac
ct
radiolog
find
sot
pulmonari
infiltr
consolid
pleural
effus
nodular
infiltr
lymphadenopathi
cavit
whilst
classic
teach
halo
air
crescent
sign
pathognomon
ia
stem
cell
transplant
patient
less
strongli
associ
ia
sot
recipi
radiolog
find
thu
reli
upon
sot
transplant
suspicion
ifd
bronchoscopi
employ
earli
evalu
possibl
ifd
high
risk
patient
small
studi
heart
sot
ia
patient
ct
find
airwayinvas
air
diseas
peribronchi
consolid
treeinbud
pattern
compar
angioinvas
diseas
ang
air
patient
later
onset
present
higher
rate
haemodialysi
frequent
intercurr
bacteri
pneumonia
greater
ia
attribut
mortal
commerci
aspergillu
gmelisa
assay
biorad
uk
detect
galactomannan
gm
cell
wall
polysaccharid
aspergillu
spp
penicillium
spp
releas
serum
growth
tissu
gmelisa
assay
less
well
valid
sot
haematolog
cohort
appear
inferior
perform
sot
cohort
clanci
et
al
describ
use
gmelisa
bronchoalveolar
lavag
bal
fluid
cohort
sot
patient
found
sensit
specif
ppv
npv
use
cutoff
studi
fals
posit
found
lung
sot
utilis
gm
cutoff
earlier
prospect
studi
gm
lung
sot
high
rate
fals
posit
also
note
particularli
amongst
cystic
fibrosi
patient
earli
post
transplant
sensit
specif
cutoff
subsequ
report
liver
lung
transplant
cohort
studi
sensit
specif
report
respect
pool
metaanalysi
examin
serum
gmelisa
sot
recipi
illustr
poor
sensit
specif
proven
probabl
respect
util
asp
pcr
sot
recipi
isol
aspergillu
spp
bal
specimen
poorli
defin
furthermor
panfung
pcr
bal
pulmonari
tissu
sot
recipi
molecular
assay
direct
detect
specif
fungi
group
fungi
report
sporad
investig
ifd
zarrinfar
et
al
demonstr
poor
correl
molecular
convent
method
diagnos
ia
bal
higher
rate
fals
posit
nest
pcr
pilot
studi
liver
lung
renal
sot
recipi
buess
et
al
studi
nest
asppcr
bal
immunosuppress
patient
sot
demonstr
low
sensit
probableproven
ifd
higher
specif
nonetheless
higher
sensit
asp
pcr
bal
demonstr
particularli
lung
sot
compar
studi
asppcr
gmelisa
lung
transplant
patient
sensit
specif
respect
lung
transplant
patient
colonis
aspergillu
spp
bal
gmelisa
compar
asppcr
higher
specif
vs
gmelisa
use
cutoff
bronchoalveolar
lavag
bal
sot
recipi
suspect
ifi
offer
promis
result
sensit
specif
respect
use
serum
bal
gmelisa
compar
small
cohort
n
predomin
lung
sot
recipi
use
cutoff
sensit
specif
probabl
proven
ia
compar
serum
sensit
specif
respect
true
util
gmelisa
asp
pcr
combin
test
bal
improv
sensit
whilst
retain
specif
hoenigl
et
al
demonstr
combin
gm
asp
pcr
sensit
specif
bal
cohort
immunocompromis
patient
includ
sot
nonetheless
variabl
sensit
gmelisa
asp
pcr
sot
recipi
compar
stem
cell
transplant
cohort
mean
investig
employ
adjunct
sole
rule
rule
test
aspergillu
lfd
pointofcar
test
use
serum
bal
diagnos
ifd
via
detect
extracellular
glycoprotein
secret
aspergillu
spp
growth
devic
sensit
specif
compar
gmelisa
result
mix
studi
haematolog
sot
recipi
suspect
ia
sensit
ia
studi
haematolog
patient
appear
lower
aspergillu
pcr
yet
higher
gmelisa
isol
nonetheless
potenti
rapid
besid
test
larger
clinic
evalu
devic
context
await
use
assay
least
extens
studi
mention
investig
pneumonia
sot
recipi
major
limit
test
gener
requir
repeat
investig
although
may
return
posit
test
infect
caus
aspergillu
spp
candida
spp
trichosporon
spp
fusarium
spp
penicillium
spp
saccharomyc
acremonium
pneumocysti
jirovecii
insensit
mucormycosi
cryptococcosi
test
therefor
current
recommend
investig
pulmonari
infiltr
sot
recipi
potenti
util
may
lie
centr
test
readili
avail
invas
method
pcp
diagnosi
ie
bronchoscopi
perform
elev
case
confirm
pcp
sensit
report
use
sot
recipi
proven
probabl
ifd
evalu
prospect
studi
bal
specimen
low
sensit
poor
specif
empir
therapi
new
pulmonari
infiltr
depend
risk
factor
clinic
present
prior
antifung
exposur
prophylaxi
empir
therapi
approach
empir
therapi
set
diagnost
algorithm
outlin
fig
approach
pulmonari
infiltr
sot
recipi
challeng
process
due
wide
rang
potenti
pathogen
presenc
pulmonari
infiltr
associ
inferior
outcom
irrespect
aetiolog
ifd
highest
associ
morbid
mortal
use
molecular
diagnost
sot
ifd
less
well
valid
stem
cell
transplant
popul
stepwis
approach
includ
multiprong
investig
stream
tailor
pretest
organ
probabl
time
post
transplant
ifd
risk
factor
local
epidemiolog
employ
